Osteoarthritis - Pipeline Insight, 2021

DelveInsight’s, “Osteoarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Osteoarthritis Understanding
Osteoarthritis: Overview
Osteoarthritis (also known as OA) is a common joint disease that most often affects middle-age to elderly people. It is commonly referred to as wear and tear of the joints, but we now know that OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments, and bone. Although it is more common in older people, it is not really accurate to say that the joints are just “wearing out.” It is characterized by breakdown of the cartilage (the tissue that cushions the ends of the bones between joints), bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining (called the synovium). OA is a top cause of disability in older people. The goal of osteoarthritis treatment is to reduce pain and improve function. There is no cure for the disease, but some treatments attempt to slow disease progression.

Osteoarthritis - Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteoarthritis pipeline landscape is provided which includes the disease overview and Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Osteoarthritis.

Osteoarthritis Emerging Drugs Chapters
This segment of the Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteoarthritis Emerging Drugs
• Ampion: Ampio Pharmaceuticals
Ampion is being developed as an intra-articular injection to treat the signs and symptoms of severe osteoarthritis of the knee (OAK), which continues to be a growing epidemic in the United States and other countries worldwide. Ampion regulates key components of the immune response connected to pain, inflammation, and joint damage in osteoarthritis. In vitro studies show that Ampion reduces the production of the cytokines responsible for inflammation (TNFα, IL-1β, IL-6, IL-12) by regulating with the genetic transcriptional pathways (NFκB, STAT) responsible for the overproduction of these cytokines while activating anti-inflammatory proteins responsible for tissue growth and healing. This mechanism of action has an overall clinical effect that has been shown to relieve pain and improve function in the knee for patients in clinical trials. Additionally, this mechanism may have the potential to stop, or reverse, disease progression after continued treatment with Ampion, which needs to be evaluated in the clinical. Currently, it is in Phase III stage of clinical trial evaluation to treat osteoarthritis.

• Lorecivivint (SM04690): Biosplice Therapeutics
Biosplice Therapeutics has developed an injectable small-molecule inhibitor of the CDC2-like kinase (CLK) and dual-specificity tyrosine regulated kinase (DYRK) family. Biosplice is conducting two large placebo-controlled phase III clinical trials where it hopes to demonstrate reduction in knee osteoarthritis pain with a single injection over the course of 6 months and 12 months, with follow-up beyond a year. Based on the mechanism of action, Biosplice is also exploring the impact lorecivivint plays on inflammation, function, and cartilage protective effects through patient reported outcomes and structural endpoints.
Further product details are provided in the report……..

Osteoarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Osteoarthritis
There are approx. 80+ key companies which are developing the therapies for Osteoarthritis. The companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Ampio Pharmaceuticals.

• Phases
DelveInsight’s report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteoarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteoarthritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteoarthritis drugs.

Osteoarthritis Report Insights
• Osteoarthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteoarthritis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Osteoarthritis drugs?
• How many Osteoarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteoarthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Osteoarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteoarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Ampio Pharmaceuticals
• Biosplice Therapeutics
• Symic Bio
• UnicoCell Biomed CO. LTD
• Eupraxia Pharmaceuticals Inc.
• Eli Lilly and Company
• Xalud Therapeutics, Inc.
• ICM Biotech Australia Pty Ltd.
• Taiwan Liposomal Company
• Gwo Xi Stem Cell Applied Technology Co., Ltd.
• Centrexion Therapeutics
• Techfields Pharma
• AstraZeneca
• Merck KGaA
• Novartis
• Antibe Therapeutics Inc.
• Bioventus LLC
• PMG Pharm Co., Ltd
• Meluha Life Sciences SDN BHD
• Anika Therapeutics
• MiMedx Group, Inc.
• Medivir
• Orient Europharma Co., Ltd.
• HSRx Biopharmaceutical
• Meiji Seika Pharma
• Peptinov
• Atlanthera
• Yuhan
• OrthoTrophix
• CartilaGen

Key Products
• Ampion
• Lorecivivint (SM04690)
• SB-061
• Elixcyte
• V120083
• Tanezumab
• XT-150
• ICM-203
• TLC599
• JointStem
• CNTX-4975-05
• X0002
• MEDI7352
• M6495
• LNA043
• ATB-346
• PTP-001
• PK101
• Chondrogen
• Cingal
• Micronized DHACM
• MIV-711
• 2ccPA
• PPV 06
• 1102-11
• YH 23537
• TPX 100
• CG 001

Executive Summary
Osteoarthritis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Ampion: Ampio Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
• Comparative Analysis
LNA 043: Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
• Comparative Analysis
PPV 06: Peptinov
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
• Comparative Analysis
CG 001: CartilaGen
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Inactive Products
• Comparative Analysis
Osteoarthritis Key Companies
Osteoarthritis Key Products
Osteoarthritis- Unmet Needs
Osteoarthritis- Market Drivers and Barriers
Osteoarthritis- Future Perspectives and Conclusion
Osteoarthritis Analyst Views
Osteoarthritis Key Companies
Table 1 Total Products for Osteoarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Osteoarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings